High FGF-21 level in a cohort of 22 patients with Dravet Syndrome—Possible relationship with the disease outcomes

Anna Ka-Yee Kwong1 | Virginia Chun-Nei Wong1 | Sheila Suet-Na Wong2 | Vanessa Loi-Yan Chu1 | Saskia Koene3 | Jan Smeitink3 | Cheuk-Wing Fung1,2

1Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
2Department of Paediatrics and Adolescent Medicine, Hong Kong Children’s Hospital, Hong Kong SAR, China
3Radboud Centre for Mitochondrial Medicine, Department of Paediatrics, Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Correspondence
Cheuk-Wing Fung, Department of Paediatrics and Adolescent Medicine, Hong Kong Children’s Hospital, Hong Kong SAR, China.
Email: fcw1209m@hku.hk

Funding information
Society for the Relief of Disabled Children

Abstract

Objective: Dravet syndrome (DS) is a severe and intractable form of epilepsy with prolonged seizures which may evolve to other seizure types and associated with mild-to-severe intellectual disabilities. Fibroblast growth factor 21 (FGF-21) is a stress hormone mediating metabolic and oxidative stress and circulating level of FGF-21 had been shown to increase in some patients with impairment of oxidative phosphorylation in muscles. In DS, FGF-21 is of interest for further study as mitochondrial oxidative stress was identified previously in patients.

Methods: Plasma FGF-21 levels were compared between 22 DS patients and 22 normal controls, and their clinical characteristics of DS patients at the time of plasma sampling were studied retrospectively. Besides, the relationships of FGF-21 level with intellectual development, seizure frequency, valproate treatment, and types of SCN1A mutations were analyzed. Logarithmic transformation of FGF-21 levels was performed before comparison and statistical analysis.

Results: Mean of log_{10} FGF-21 level was significantly higher in DS patients when comparing with normal controls (P = .0042). Mean of log_{10} FGF-21 level was significantly higher in DS patients with normal-to-mild ID versus mild-to-severe ID (P = .0193) and with valproate treatment versus without valproate treatment (P = .015). No significant difference was shown in FGF-21 level in DS patients with missense versus truncating SCN1A variants, and no correlation could be demonstrated between seizure frequency and FGF-21 level.

Significance: Significantly higher level of plasma FGF-21 was identified in DS patients. The high FGF-21 levels were shown to be associated with developmental outcome and valproate treatment. These results support further investigation on the relationship of FGF-21 with the clinical outcomes of DS and other related mechanism which is important for possible therapeutic development for this epileptic encephalopathy.
**INTRODUCTION**

Dravet syndrome (DS) is a severe form of epileptic encephalopathy with prolonged febrile or afebrile seizures which may evolve to other seizure types.\(^1,2\) Overall, DS is poorly responsive to antiseizure drugs (ASDs). DS patients have seizure onset in the first year and developmental delay from the second year of life. Most patients have mild-to-severe intellectual disabilities. The majority (70%-80%) was found to have pathogenic variants in the \(SCN1A\) gene encoding the \(\alpha1\) pore-forming subunit of the voltage-gated sodium channel.\(^3\) The degree of developmental delay in DS can be associated with the types of \(SCN1A\) variants as reported in our previous study of 18 DS cases\(^4\) and other developmental modifiers such as defective mitochondrial oxidative phosphorylation found in other studies.\(^5,6\)

Fibroblast growth factors (FGFs) are a family of polypeptide growth factors which mediate various biological processes including embryonic development, angiogenesis, tissue repair, homeostasis, and metabolism regulation.\(^7,8\) In vertebrates, 23 family members (FGF1-23) have been identified\(^9\) and they are structurally related signaling molecules participating in different pathophysiological processes by paracrine and endocrine secretion. FGF-21 is a circulating cytokine acting as a metabolic regulator for glucose and lipid metabolism.\(^10\) It is suggested to be a stress hormone-mediating responder to metabolic and oxidative stress.\(^10,12\) Elevation of serum FGF-21 was found in patients with impairment of oxidative phosphorylation in muscle, and thus, FGF-21 had been proposed as a biomarker for muscle-manifesting mitochondrial diseases.\(^13\) Kim et al.\(^11\) speculated that FGF-21 may be an adaptive regulator to counteract muscle stress caused by mitochondrial dysfunction based on the demonstration of positive effect of FGF-21 on mitochondrial function and oxidative capacity.\(^14\) The brain is particularly vulnerable to mitochondrial oxidative stress and previous in vitro and in vivo studies had been demonstrated that FGF-21 might possess a neuroprotective role in central nervous system.\(^15,16\)

As elevation of circulating FGF-21 had been documented in patients with muscle-manifesting mitochondrial diseases, we tried to investigate the FGF-21 level in other severe neurological diseases and found that it was also elevated in DS. In this study, we have retrospectively measured the FGF-21 concentration of stored plasma in a small cohort of DS patients and normal controls. FGF-21 levels in DS patients versus normal controls and the FGF-21 level in DS patients with different clinical features including intellectual development, seizure frequency, ASDs, and the types of \(SCN1A\) mutations were then compared. High FGF-21 levels in DS patients and their correlation with clinical outcome suggest further studies on the neuroprotective role of FGF-21 as a possible biomarker or therapeutic agent in DS.

**METHODS AND MATERIALS**

Twenty-two patients diagnosed to have DS were enrolled from the Neurology Clinic of Queen Mary Hospital and Duchess of Kent Children’s Hospital. The normal controls consisted of 22 age-matched healthy children.

The DS patients were identified based on International League Against Epilepsy (ILAE) classification (2017)\(^1\) and core DS phenotypes defined by Dravet.\(^2\) Intellectual disability (ID) was assessed according to their scores of developmental/intelligence quotients as mild ID (quotient = 50-70), moderate ID (quotient = 25-50), or severe ID (quotient < 25).

The genetic information of 15 DS patients in our cohort has been reported in our previous study.\(^4\) For the remaining 7 DS patients, all exons covering the coding regions, as well as the splice junctions of \(SCN1A\), were amplified by polymerase chain reaction (PCR) and sequenced. Variant analysis was performed by alignment with the reference genomic sequences (GeneBank accession no.: NG_011906). Variants were discriminated from single nucleotide polymorphisms (SNP) reported in NCBI SNP and Ensembl SNP database.
Missense variants were predicted to be deleterious to protein function by homology-based tool PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) and SIFT (http://sift.bi.a-star.edu.sg/). Splice site variants in intron regions were analyzed by another online software tool, the Automated Splice Site Analyses (https://splice.uwo.ca). MLPA was performed in one DS patient using SALSA MLPA probemix (P137-B2, MRC-Holland, Amsterdam, The Netherlands).

Plasma samples were previously collected from DS patients and normal controls. Samples were stored at −80°C until analysis. Plasma FGF-21 concentrations were measured in duplicate by enzyme-linked immunosorbent assay (ELISA) for FGF-21 (BioVendor, Brno, Czech Republic) according to the manufacturer’s instructions. The FGF-21 concentrations were calculated from the standard curve constructed from standards provided by the kit.

Plasma FGF-21 levels were compared between 22 DS patients and 22 normal controls and the clinical characteristics of DS patients at the time of plasma sampling were studied retrospectively. The FGF-21 levels were compared between DS patients with mild-to-normal versus moderate-to-severe intellectual disabilities, with versus without valproate treatment, with missense versus truncated SCN1A variants. Logarithmic transformation of FGF-21 levels was performed before comparison of the means of two groups by unpaired t-test. The correlation seizure frequency with the transformed FGF-21 levels was statistically tested by Pearson correlation analysis. Besides, seizure frequency was compared between the DS patients with and without valproate treatment by unpaired t-test.

This study was approved by the Institutional Review Board of the Hong Kong West Cluster and the University of Hong Kong (IRB Ref. No.: UW 11-190 and UW 13-443).

3 | RESULTS

The cohort of 22 DS patients were all confirmed to have SCN1A mutations. Fifteen DS patients in our cohort have been reported to have pathogenic SCN1A variants in our previous study.\(^4\)\(^5\)\(^6\) DS patients were also identified with missense, splice site SCN1A variants, and the remaining one was found to have deletion of exon 14-16 in SCN1A gene (Table 1). The normal controls consisted of 22 healthy children, age ranging from 2 months to 15 years (Table S1), were matched with the age of the DS patients ranging from 2 years 8 months to 23 years (Table 1). The plasma FGF-21 concentrations and the clinical characteristics including intellectual disability, seizure frequency at the time of plasma sampling of the DS patients were also shown in Table 1.

Plasma FGF-21 concentration ranged from 1.3 to 231.7 pg/mL in normal controls and ranged from 0 to 6378.6 pg/mL in DS patients. When comparing between DS patients and normal controls, mean of log\(_{10}\) FGF-21 level was significantly higher in DS patients (Mean ± SEM: 2.415 ± 0.2043; n = 22) than normal controls (Mean ± SEM: 1.681 ± 0.1309; n = 22) by unpaired t-test (two-tailed P value = .0042) (Figure 1).

When comparing among 22 DS patients, mean of log\(_{10}\) FGF-21 level was significantly higher in DS patients with normal-to-mild ID (Mean ± SEM: 2.734 ± 0.2261; n = 13) with those with moderate to severe ID (Mean ± SEM: 1.766 ± 0.3138; n = 8) by unpaired t-test (two-tailed P value = .0193) (Figure 2A). In addition, the mean of log\(_{10}\) FGF-21 level was significantly higher in DS patients with valproate treatment (Mean ± SEM: 2.741 ± 0.1842; n = 15) than normal controls (Mean ± SEM: 1.716 ± 0.4125; n = 7) by unpaired t-test (two-tailed P value = .015) (Figure 2B). Moreover, treatment with valproate did not result in major liver function derangement. For SCN1A variants, mean of log\(_{10}\) FGF-21 level of DS patients with missense variants (Mean ± SEM: 2.439 ± 0.3741; n = 10) has no significant difference from those with truncated variants (Mean ± SEM: 2.395 ± 0.2249; n = 12) by unpaired t-test (two-tailed P value = .916) (Figure 2C). There is no significant association between valproate treatment (with versus without valproate treatment) and the developmental outcome (normal-to-mild versus moderate-to-severe ID) of the DS patients by chi-square analysis.

When considering the seizure frequencies of DS patients at the time of plasma sampling, there was no correlation between number of seizures per month and log\(_{10}\) FGF-21 level (Pearson correlation coefficient = −0.1664, P = .459) (Figure 3). There is no significant difference in seizure frequency of DS patients with valproate treatment (Mean ± SEM: 3.267 ± 1.073; n = 15) and without valproate treatment (Mean ± SEM: 4.214 ± 1.546; n = 7) by unpaired t-test (two-tailed P value = .6223) (Figure 2D).

4 | DISCUSSION

4.1 | Relationship of high FGF-21 with oxidative stress

We found a significantly higher plasma FGF-21 level in the DS patients when comparing with normal controls and some levels in DS patients were very high which is comparable to those in patients with oxidative phosphorylation disorders.\(^13\) Recently, mitochondrial bioenergetics and gluconeogenesis were proven to be impaired in a zebrafish model of DS.\(^11\) Previous studies had also shown mitochondrial oxidative phosphorylation dysfunction in\(^5\)\(^6\) 2 DS patients who fulfilled the adult diagnostic
**Table 1** Clinical features of 22 patients with Dravet syndrome (DS)

| Case | Age at plasma sampling | FGF-21 (pg/mL) | Intellectual disability | Seizure frequency per month | Type of seizures | SCN1A variants | Valproate treatment (+/−) | Other concomitant ASDs |
|------|------------------------|----------------|------------------------|-----------------------------|------------------|----------------|-------------------------|------------------------|
| 6    | 22 y                   | 80.6           | Moderate               | 2.5                         | Generalized tonic seizures | Frameshift c.2971_2972delinsG, p.(Leu991Valfs*2) | − | Clobazam, Topiramate, Phenytoin |
| 24   | 14 y                   | 544.2          | Moderate               | 1                           | Generalized tonic clonic seizures | Splice site IVS21 + 1G > A | + | Clobazam |
| 40   | 9 y                    | 0 (lower than detectable level) | Moderate | <1                      | Multiple seizure types (Generalized tonic clonic, typical absence, generalized onset myoclonic, focal aware seizures) | Missense c.2378C > T, p.(Thr793Met) | − | Clonazepam, Keppra |
| 46   | 9 y                    | 330.6          | Mild                   | <1                         | Multiple seizure types (Generalized tonic clonic, typical absence, generalized onset myoclonic, focal aware seizures) | Missense c.311C > T, p.(Ala104Val) | + | Only Valproate has been used |
| 53   | 7 y                    | 977.4          | Normal                 | 2                          | Generalized tonic clonic seizures | Nonsense c.1348C > T, p.(Gln450*) | + | Clobazam |
| 65   | 8 y                    | 40.6           | Mild                   | 6.5                        | Generalized tonic clonic seizures | Missense c.4834G > A, p.(Val1612Ile) | − | Clobazam, Levetiracetam, Carbamazepine |
| 71   | 15 y                   | 8.6            | Moderate               | 4                          | Generalized tonic clonic seizures | Nonsense c.569G > A, p.(Trp190*) | + | Lamotrigine, Clobazam, Lorazepam |
| 74   | 11 y                   | 151.0          | Moderate               | 3.5                        | Generalized tonic clonic seizures | Missense c.2214G > A, p.(Trp738*) | + | Topiramate |
| 75   | 13 mo                  | 783.3          | Mild                   | 9                          | Multiple seizures type (Focal aware motor, focal impaired awareness motor, generalized tonic clonic seizures) | Missense c.1177C > T, p.(Arg393Cys) | + | Topiramate |
| 76   | 9 mo                   | 24.5           | Normal                 | 2.5                        | Generalized tonic clonic seizures | Missense c.1264G > A, p.(Val422Met) | − | Phenobarbione, phenytoin |
| 77   | 3 y                    | 1712.1         | Mild                   | 1.5                        | Generalized tonic clonic seizures | Frameshift c.4229delA, p.(Asn140Metfs*2) | + | Clobazam, Levetiracetam |
| 85   | 23 y                   | 72.4           | Moderate               | 11                         | Generalized tonic clonic seizures | Nonsense c.1053T > A, p.(Cys351*) | − | Clobazam, Topiramate, Levetiracetam |

(Continues)
| Case | Age at plasma sampling | FGF-21 (pg/mL) | Intellectual disability | Seizure frequency per month | Type of seizures | SCN1A variants | Valproate treatment (+/−) | Other concomitant ASDs |
|------|------------------------|----------------|-------------------------|----------------------------|------------------|----------------|--------------------------|-----------------------|
| 89   | 2 y 8 mo               | 34.3           | Mild                    | 7                          | Generalized tonic clonic seizures | Splice site IVS3 + 3A > C | −                       | Clobazam, Oxcarbazepine |
| 94   | 4 y                    | 6378.6         | Mild                    | 2                          | Recurrent febrile status epilepticus with generalized tonic clonic seizures, focal to bilateral tonic clonic seizure, absence seizures. | Missense c.3641T > G, p.(Ile1214Arg) | +                       | Clobazam |
| 100  | 13 mo                  | 270.1          | Normal                  | 1.5                        | Generalized tonic clonic seizures | Frameshift c.4558delC, p.(Gln1520Lysfs*19) | +                       | Clobazam |
| 101  | 11 y                   | 289.3          | Moderate to severe      | 16                         | Generalized tonic clonic seizures | Splice site IVS24-1G > T | +                       | Clobazam |
| 102  | 4 y                    | 2921.2         | NA                      | 0                          | Generalized tonic clonic seizures, focal aware motor seizure | Missense c.380A > T; p.(His127Leu) | +                       | Clobazam, Stiripentol |
| 103  | 19 mo                  | 4409.9         | Normal                  | 1                          | Focal aware motor seizure, focal impaired awareness motor seizures | Missense c.965G > T; p.(Arg322Ile) | +                       | Zonisamide |
| 104  | 6 y                    | 774.3          | Normal                  | 3                          | Generalized tonic clonic seizures | Missense c.4988T > G, p.(Leu1663Trp) | +                       | Levetiracetam |
| 105  | 4 y                    | 5180.4         | Mild                    | 0                          | Generalized tonic clonic seizures | Splice site IVS12 + 2T > A | −                       | Clobazam |
| 106  | 3 y                    | 111.8          | Moderate                | 1                          | Generalized tonic clonic seizures | Nonsense c.361I1G > A; p.(Trp1204*) | +                       | Clobazam, Topiramate |
| 107  | 2 y 10 mo              | 769.5          | Normal                  | 3.5                        | Generalized tonic clonic seizures | Deletion from exon 14 to exon 16 | +                       | Clobazam |

y = years; mo = months; GGT = gamma-glutamyl transferase (values expressed as IU/L); ALT = alanine aminotransferase (values expressed as IU/L); NA: clinical information is not available; ASDs: antiseizure drugs. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.
Another study showed a low cellular complex III amount, severe decline in complex III activity and significant reduction of mitochondrial ATP content in skin fibroblasts of 4 DS patients. The study showed no correlation of total mtDNA, mitochondrial haplogroups and POLG variants with the defective mitochondrial respiratory chain. They proposed that cells under oxidative stress in DS increase free radical production which worsens clinical phenotypes in addition to the effect of the Nav 1.1 defect. Mitochondrial oxidative stress of DS patients, therefore, may be a possible reason for the stimulation of circulating FGF-21. Further investigation should be considered to understand whether oxidative stress and mitochondrial dysfunction are involved in DS patients. Skin fibroblast cells from the DS patients or mice with SCN1A knockout allele can be used as in vitro and vivo models to study the mitochondrial functions including the complex activities, ATP production rate, membrane potential, and reactive oxygen species (ROS) production.

### 4.2 Association of high FGF-21 with clinical outcome

In the present study, clinical outcomes including seizure frequency and degree of intellectual disability were analyzed retrospectively in DS patients. The FGF-21 level was significantly higher in the groups of patients with milder ID. Although there was no correlation between seizure frequency and FGF-21 level by statistical analysis, the patients with higher FGF-21 level tended to have lower seizure frequencies in our data. It is possible that FGF-21 acts as an adaptive regulator produced in the DS patients with compensatory response. For those DS patients with even higher FGF-21 and milder phenotypes, these may be due to the counteracting effect of FGF-21 on the disease stress to improve the clinical outcome. However, this is only a hypothesis and a more comprehensive study with a larger sampling size should be used to investigate the association of FGF-21 level with clinical outcomes in DS or other epilepsy syndromes.

FGF-21 was considered to be an important regulator of mitochondrial oxidative stress and had therapeutic potential to attenuate cell damage and death, endoplasmic reticulum stress, and inflammation. Previous study suggested that FGF-21 increase is a compensatory response elicited by mitochondrial respiratory chain deficiency to enhance mitochondrial function in skeletal muscle. In central nervous system, FGF-21 was also suggested to have neuroprotective function. In human dopaminergic neuronal cells, FGF-21 was shown to increase mitochondrial respiratory capacity, biogenesis and functions. Study of obese, insulin resistant rat model illustrated the effect of FGF-21 on prevention of cognitive decline which is associated with its abilities to improve hippocampal synaptic plasticity, dendritic spine density, brain mitochondrial function, and attenuate brain cell apoptosis. If there are more evidence to prove the association of FGF-21 level with clinical outcomes, further studies could be done to investigate the mechanism of FGF-21 induction in DS patients and correlation with milder ID. It remains to be discovered whether upregulation of circulating FGF-21 may be a compensatory mechanism to protect the neuronal cells from severe damages under metabolic or oxidative stress in DS patients.

### 4.3 Effect of valproate treatment to FGF-21 level

We also found that FGF-21 levels were significantly higher in DS patients who received valproate treatment. In vitro studies had illustrated that valproate upregulated FGF-21 expression in primary neurons or cortical glial cells. Another study on adult patients with depressed bipolar disorder received valproate treatment (500-1000 mg daily) for 12 weeks showed a significant increase in FGF-21 level from 167.7 to 207.1 pg/mL. However, this increase in circulating FGF-21 was not as high as those found in our DS cohort. Nevertheless, valproate may not be the sole factor to induce FGF-21 but may possibly act synergistically with other factors such as mitochondrial oxidative stress in DS to trigger the release of FGF-21. In another recent study, valproate was suggested to have a neuroprotective effect through epigenetic mechanisms by modulation of histone deacetylases (HDACs) influencing different gene expression and FGF21 is one of the genes suggested to be upregulated by valproate through HDACs.

### 4.4 Limitations

The retrospective nature is the limitation of the present study. One should set up a standard sampling protocol for
FGF-21 measurement at different time courses to understand the variation of FGF-21 level in different clinical conditions such as seizure frequency, intellectual development, or clinical responses to ASDs. The time of plasma sampling is important to be fixed because of the diurnal rhythm of circulating FGF21 as suggested in a previous study.24

As FGF-21 may be elevated in obesity,25 nutrition and body mass index could be potential confounding factors that may affect the metabolic status and hence the FGF-21 levels. Such factor would have to be further investigated in the future studies to prove the direct relationship between DS and FGF-21.

4.5 | Clinical relevance or future directions

FGF-21 has the potential to be developed as a biomarker to monitor the severity and treatment response in DS if a comprehensive study with a larger sampling size can be further

**FIGURE 2** Comparison of plasma FGF-21 concentrations (pg/mL) and seizure frequency in patients with Dravet syndrome (DS) (A) Log10 FGF-21 level in DS patients with mild-to-normal versus moderate-to-severe intellectual disabilities (ID); (B) Log10 FGF-21 in DS patients with versus without valproate treatment; (C) Log10 FGF-21 level in DS patients with missense versus truncating SCN1A variants; (D) Seizure per month in DS patients with versus without valproate treatment. Mean of log10 FGF-21 level of the two groups were compared using unpaired t-test and 2-tailed P-values <.05* were considered significant. Horizontal lines indicated mean of log10 FGF-21

**FIGURE 3** Correlation of seizure frequency and plasma FGF-21 concentrations in patients with Dravet syndrome (DS)
carried out. In addition, the neuroprotective mechanisms of FGF-21 and the relationship with mitochondrial dysfunction can be further investigated for a possible therapeutic target for DS or other epilepsy syndromes.

5 | CONCLUSION

In conclusion, we identified significantly higher plasma FGF-21 levels in DS patients when compared with normal controls. Besides, the high FGF-21 levels were shown to be associated with better developmental outcomes and valproate treatment. Further study on the relationship of FGF-21 with the clinical outcomes and other related mechanisms will be important for possible therapeutic development for DS. Use of FGF-21 as a potential predictor of neurodevelopmental outcome may be considered in our clinical practice.

ACKNOWLEDGEMENT

We would also like to acknowledge the Society for the Relief of Disabled Children for donations for this study. We acknowledge the Centre of Genomic Sciences, The University of Hong Kong for providing the sequencing service. We acknowledge our colleagues in Division of Clinical Biochemistry, Department of Pathology, The Queen Mary Hospital for providing us the genetic information of one of the DS patients with deletion in SCN1A gene and their support on FGF-21 ELISA for healthy controls.

CONFLICT OF INTEREST

Anna Ka-Yee Kwong, Virginia Chun-Nei Wong, Wong Sheila Suet-Na, Vanessa Loi-Yan Chu, Saskia Koene, and Cheuk-Wing Fung declare that they have no conflict of interest. Jan Smeitink is the CEO of Khondrion, a pharmaceutical company developing compounds to potentially treat mitochondrial disease.

ORCID

Anna Ka-Yee Kwong https://orcid.org/0000-0001-5133-1019

REFERENCES

1. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhot L, et al ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512–21.
2. Dravet C. The core Dravet syndrome phenotype. Epilepsia. 2011;52(Suppl 2):3–9.
3. Depienne C, Trouillard O, Saint-Martin C, Gourfinkel-An I, Bouteiller D, Carpentier W, et al Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients. J Med Genet. 2009;46(3):183–91.
4. Kwong AK, Fung CW, Chan SY, Wong VC. Identification of SCN1A and PCDH19 mutations in Chinese children with Dravet syndrome. PLoS One. 2012;7(7):e41802.
5. Craig AK, de Menezes MS, Saneto RP. Dravet syndrome: patients with co-morbid SCN1A gene mutations and mitochondrial electron transport chain defects. Seizure. 2012;21(1):17–20.
6. Doccini S, Meschini MC, Mei D, Guerrini R, Sicca F, Santorelli FM. Mitochondrial respiratory chain defects in skin fibroblasts from patients with Dravet syndrome. Neurol Sci. 2015;36(11):2151–5.
7. Yun Y-R, Won JE, Jeon E, Lee S, Kang W, Jo H, et al Fibroblast growth factors: biology, function, and application for tissue regeneration. J Tissue Eng. 2010;2010:218142.
8. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009;8(3):235–53.
9. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol. 2001;2(3):3005.
10. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswaran V, et al Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007;5(6):415–25.
11. Kim KH, Lee MS. FGF21 as a mediator of adaptive responses to stress and metabolic benefits of anti-diabetic drugs. J Endocrinol. 2015;226(1):R1–16.
12. Gomez-Samano MA, Grajales-Gomez M, Zuurth-Vazquez JM, Navarro-Flores MF, Martinez-Saavedra M, Juarez-Leon OA, et al Fibroblast growth factor 21 and its novel association with oxidative stress. Redox Biol. 2017;11:335–41.
13. Suomalainen A, Elo JM, Pietilainen KH, Hakonen AH, Sevastianova K, Korpela M, et al FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. Lancet Neurol. 2011;10(9):806–18.
14. Chau MD, Gao J, Yang Q, Wu Z, Gromada J. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC1alpha pathway. Proc Natl Acad Sci USA. 2010;107(28):12553–8.
15. Leng Y, Wang Z, Tsai LK, Leeds P, Fessler EB, Wang J, et al FGF-21, a novel metabolic regulator, has a robust neuroprotective role and is markedly elevated in neurons by mood stabilizers. Mol Psychiatry. 2015;20(2):215–23.
16. Su-Nguanmoo P, Tanajak P, Kerdphee S, Satjaritanun P, Wang X, Liang G, et al FGF21 improves cognition by restored synaptic plasticity, dendritic spine density, brain mitochondrial function and cell apoptosis in obese-insulin resistant male rats. Horm Behav. 2016;85:86–95.
17. Banerji R, Huynh C, Figueroa F, Dinday MT, Baraban SC, Patel M. Enhancing glucose metabolism via gluconeogenesis is therapeutic in a zebrafish model of Dravet syndrome. Brain commun. 2021;3(1).
18. Bernier FP, Boneh A, Dennett X, Chow CW, Cleary MA, Thorburn DR. Diagnostic criteria for respiratory chain disorders in adults and children. Neurology. 2002;59(9):1406–11.
19. Ji K, Zheng J, Lv J, Xu J, Xi J, Luo YB, et al Skeletal muscle mitochondrial respiration is dependent on FGF-21 and its novel association with oxidative stress. Redox Biol. 2017;11:335–41.
20. Makela J, Tselykh TV, Maiorana F, Eriksson O, Do HT, Mudo G, et al FGF21 increases mitochondrial functions and increases the activity of PGC-1alpha in human dopaminergic neurons via Sirtuin-1. SpringerPlus. 2014;3:2.
21. Leng Y, Wang J, Wang Z, Liao HM, Wei M, Leeds P, et al Valproic acid and other HDAC inhibitors upregulate FGF21 gene expression and promote process elongation in glia by inhibiting HDAC2 and 3. Int J Neurpsychopharmacol. 2016;19(8):1–13.
22. Chang HH, Chen PS, Cheng YW, Wang T-Y, Yang YK, Lu R-B. FGF21 is associated with metabolic effects and treatment response in depressed bipolar II disorder patients treated with valproate. Int J Neuropsychopharmacol. 2017;pyx093.

23. Romoli M, Mazzochetti P, D’Alonzo R, Siliquini S, Rinaldi VE, Verrotti A, et al. Valproic acid and epilepsy: from molecular mechanisms to clinical evidences. Curr Neuropharmacol. 2019;17(10):926–46.

24. Yu H, Xia F, Lam KS, Wang Y, Bao Y, Zhang J, et al. Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. Clin Chem. 2011;57(5):691–700.

25. Tillman EJ, Rolph T. FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases. Front Endocrinol. 2020;11:601290.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Kwong AK-Y, Wong VC-N, Wong SS-N, et al. High FGF-21 level in a cohort of 22 patients with Dravet Syndrome—Possible relationship with the disease outcomes. Epilepsia Open. 2021;6:685–693. https://doi.org/10.1002/epi4.12534